We are a gene therapy startup located  @MaRS Toronto


Screen Shot 2017-08-28 at 7.18.20 PM.png



Mediphage Bioceuticals Acts Locally to Make a Global Impact.

We are committed to developing gene therapy platforms that enable the development of in-need therapeutics. We act with integrity, honesty, and are committed to bettering mankind in a safe and efficacious way. We form partnerships with leading pharmaceutical companies and thought leaders to enable a global impact. 


December, 2015

Mediphage Bioceuticals Inc. was formed as a spin off company from the University of Waterloo in Ontario, Canada.

Seed Round.

March, 2016

Mediphage Bioceuticals closes its seed round of 490K to develop proof of concept and perform early stage efficacy studies.

Concept Testing.

February, 2017

Mediphage Bioceuticals successfully develops its DNA Ministring production and targeting technology. Mediphage also completes early stage concept and efficacy studies.

MARS Toronto.

March, 2017

Mediphage Bioceuticals moves to the MaRS Innovation Center located in Toronto, Ontario. Mediphage Bio is now entering late stage safety and efficacy studies and is beginning to manufacture DNA Ministrings in compliance with cGMP manufacturing practices.



Screen Shot 2017-08-28 at 8.52.21 PM.png

A Featured Platform

Our Patented DNA ministrings are the safest and most efficacious DNA vectors for nonviral gene delivery. Their topology as linear covalently closed (stable) “strings” makes them the safest tools for therapeutic DNA delivery or genomic manipulation to date.

We designed the production platform this way from inception, and we have tested and published these outcomes in Nature affiliate journals. DNA ministrings are made through a simple shift in temperature in bacteria which makes them scalable and inexpensive to produce versus competitors that fall dramatically short in terms of production efficiency. Our current application targets colorectal (CRC) as proof of principle. Future targets include prostate cancer, intractable disease and monogenic disorders such as cystic fibrosis

Screen Shot 2017-09-17 at 4.29.34 PM.png

We are pioneering the use of ministrings to deliver toxic and therapeutic genes as a novel colorectal and ovarian cancer gene therapy strategy. Toposiomerases modulate DNA topology by relaxing supercoils and controlling torsion in the DNA helix. They do so via transient cleavage of the DNA helix. Topoisomerase inhibitors or “poisons” include anthracyclines such as doxorubicin and daunorubicin and are common cancer chemotherapeutics. Topoisomerase poisons stabilize topoisomerase-mediated intermediates, leading to an accumulation of double-stranded DNA breaks, which in turn induces apoptosis or cell death. We aim to encode specific negative dominant mutant topoisomerase alleles that simulate the activity of toxic topoisomerase inhibitor-derived intermediates without the need for toxic topoisomerase poison addition. 


Ovarian & Colorectal Cancer


Management Team


Dr. Roderick Slavcev,

Founder & CEO, HBSc, PhD, MBA, MRSB, C.Biol

  • Associate Professor, Pharmaceutical Sciences
  • Professor, Business & Entrepreneurship School of Pharmacy, University of Waterloo

  • Chartered Biologist, Royal Society of Biology


Dr. Jonathan Blay,


  • Professor of Pharmacy (Waterloo)
  • Adjunct Professor of Pathology (Dalhousie)

  • Fellow of the Institute of Biomedical Sciences

  • Fellow of the Royal Society of Biology


Shirley Wong

Senior Scientist, BSc

  • PhD Candidate
  • School of Pharmacy
  • University of Waterloo
Shirley Wong Headshot.png

Lee Bowman,

Director of Advancement

  • MA - International Relations
  • BMath - Computer Science (Bioinformatics)
Lee Bowman Headshot.png


Chief Operating Officer

  • MBET - Business Entrepreneurship, and Technology
  • HBSc - Neuroscience, Cell and Molecular Biology, and Immunology
Vanessa Ferlaino Headshot_formatted.png

Advisory Board


Dr. Grant Isaac,
CFO, Cameco


Dr. Sanjay Singh, President & CEO, Temple Therapeutics B.V. Director, BioteCanada


Dr. Michael Naso,
Director R&D, Johnson & Johnson


Dr. Jake Thiessen, Associate Dean and Founder, University of Waterloo, School of Pharmacy (retired)